Rationale, design, and baseline characteristics in Evaluation of LIXisenatide in Acute Coronary Syndrome, a long-term cardiovascular end point trial of lixisenatide versus placebo

Date
2015
Author
Solomon, Scott D.
Wu, Yujun
Pfeffer, Marc A.
Claggett, Brian
Diaz, Rafael
Dickstein, Kenneth
Gerstein, Hertzel C.
Johnston, Peter
Kober, Lars V.
Lawson, Francesca
Lewis, Eldrin F.
Maggioni, Aldo P.
McMurray, John J. V.
Ping, Lin
Probstfield, Jeffrey L.
Tardif, Jean-Claude
Bentley-Lewis, Rhonda
Aguilar, David
Riddle, Matthew C.
Metadata
Show full item record
Abstract
Background Cardiovascular (CV) disease is the leading cause of morbidity andmortality in patients with type 2 diabetes mellitus (T2DM). Furthermore, patients with T2DM and acute coronary syndrome (ACS) have a particularly high risk of CV events. The glucagon-like peptide 1 receptor agonist, lixisenatide, improves glycemia, but its effects on CV events have not been thoroughly evaluated.
URI
http://hdl.handle.net/20.500.12627/177617
https://doi.org/10.1016/j.ahj.2015.02.002
Collections